Pultegroup Free cash flow decreased by 81.8% to $134.36M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 28.4%, from $104.62M to $134.36M. Over 3 years (FY 2021 to FY 2025), Free cash flow shows an upward trend with a 23.4% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $238.53M | $95.57M | $435.15M | $176.98M | -$432.30M | $948.32M | $687.63M | $717.88M | $435.28M | $263.78M | $215.71M | $386.24M | $417.17M | $543.13M | $104.62M | $252.97M | $651.13M | $739.81M | $134.36M |
| QoQ Change | — | -59.9% | +355.3% | -59.3% | -344.3% | +319.4% | -27.5% | +4.4% | -39.4% | -39.4% | -18.2% | +79.1% | +8.0% | +30.2% | -80.7% | +141.8% | +157.4% | +13.6% | -81.8% |
| YoY Change | — | — | — | — | -552.3% | +117.9% | +288.5% | — | +200.7% | -72.2% | -68.6% | -46.2% | -4.2% | +105.9% | -51.5% | -34.5% | +56.1% | +36.2% | +28.4% |